Betaxolol and levobunolol: new beta-blocking antiglaucoma agents.

Abstract

The Food and Drug Administration has recently approved the use of two new ophthalmic beta-adrenergic antagonistic agents: betaxolol hydrochloride (Betoptic) and levobunolol hydrochloride (Betagan). This paper reviews the history, pharmacologic properties, clinical efficacy and potential side effects of this expanding class of antiglaucoma medication.

Cite this paper

@article{Tierney1987BetaxololAL, title={Betaxolol and levobunolol: new beta-blocking antiglaucoma agents.}, author={Dr. William M. Tierney}, journal={Journal of the American Optometric Association}, year={1987}, volume={58 9}, pages={722-7} }